SUMMARY, EXPLANATION AND LIMITATIONS:
CD79 is composed of the glycoproteins CD79α (40 – 45 kDa) and CD79β (37 kDa). Both components form the disulfid-linked heterodimer CD79 (82 – 95 kDa). The B-cell antigen receptor complex is formed via association of CD79a with membrane-bound immunoglobulins.
Expression of CD79a is largely restricted to B-cell lineage. However, CD79a is coexpressed with CD3. According to Pilozzi et al. CD79a positive T-lymphoblastic leukaemias/lymphomas are also positive for CD3, whereas cases of Blymphoblastic leukaemias/lymphomas are CD3 negative and CD79a positive.
Initially, CD79a exists in precursor B-cells as cyCD79 in the cytoplasm. During the pro B-cell phase expression on the cell surface starts and remains during the whole differentiation. At the beginning of plasma cell differentiation CD79 expression is stopped. Eventually, only a small amount of plasma cells contain CD79. CD79a is stronger expressed by B-cells of the follicular mantel zone than by cells in the germ centre.
Anti-CD79a antibody of clone SP18 is helpful for identification of B-cell neoplasias of all stages of maturity.
Immunogen: Synthetic peptide corresponding to the N-terminus of human CD79a.
Staining pattern: Cell membrane.
Positive control: Tissue sample from tonsil or lymph node.
This antibody is designed for the specific localization of human CD79a using IHC techniques in formalin-fixed, paraffin-embedded tissue sections.
CD79α is an excellent marker of B cells and tumors derived from them, with particularly useful for the identification of infiltration by pre-B acute leukemias and lymphomas with plasmacytoid differentiation intense. T-cell lymphomas and myeloid neoplasms are negative in a very constant.